191 related articles for article (PubMed ID: 14656474)
1. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
[TBL] [Abstract][Full Text] [Related]
2. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
Clarke TR; Hoshiya Y; Yi SE; Liu X; Lyons KM; Donahoe PK
Mol Endocrinol; 2001 Jun; 15(6):946-59. PubMed ID: 11376113
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
4. The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling.
Visser JA; Olaso R; Verhoef-Post M; Kramer P; Themmen AP; Ingraham HA
Mol Endocrinol; 2001 Jun; 15(6):936-45. PubMed ID: 11376112
[TBL] [Abstract][Full Text] [Related]
5. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
Pieretti-Vanmarcke R; Donahoe PK; Pearsall LA; Dinulescu DM; Connolly DC; Halpern EF; Seiden MV; MacLaughlin DT
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17426-31. PubMed ID: 17088539
[TBL] [Abstract][Full Text] [Related]
6. Mullerian Inhibiting Substance induces NFkB signaling in breast and prostate cancer cells.
Hoshiya Y; Gupta V; Segev DL; Hoshiya M; Carey JL; Sasur LM; Tran TT; Ha TU; Maheswaran S
Mol Cell Endocrinol; 2003 Dec; 211(1-2):43-9. PubMed ID: 14656475
[TBL] [Abstract][Full Text] [Related]
7. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
8. AMH signaling: from receptor to target gene.
Visser JA
Mol Cell Endocrinol; 2003 Dec; 211(1-2):65-73. PubMed ID: 14656478
[TBL] [Abstract][Full Text] [Related]
9. Genetic studies of the AMH/MIS signaling pathway for Müllerian duct regression.
Jamin SP; Arango NA; Mishina Y; Hanks MC; Behringer RR
Mol Cell Endocrinol; 2003 Dec; 211(1-2):15-9. PubMed ID: 14656471
[TBL] [Abstract][Full Text] [Related]
10. Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor.
Gouédard L; Chen YG; Thevenet L; Racine C; Borie S; Lamarre I; Josso N; Massague J; di Clemente N
J Biol Chem; 2000 Sep; 275(36):27973-8. PubMed ID: 10854429
[TBL] [Abstract][Full Text] [Related]
11. Components of the anti-Müllerian hormone signaling pathway in gonads.
di Clemente N; Josso N; Gouédard L; Belville C
Mol Cell Endocrinol; 2003 Dec; 211(1-2):9-14. PubMed ID: 14656470
[TBL] [Abstract][Full Text] [Related]
12. Mullerian inhibiting substance recruits ALK3 to regulate Leydig cell differentiation.
Wu X; Zhang N; Lee MM
Endocrinology; 2012 Oct; 153(10):4929-37. PubMed ID: 22872577
[TBL] [Abstract][Full Text] [Related]
13. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
Zhan Y; Fujino A; MacLaughlin DT; Manganaro TF; Szotek PP; Arango NA; Teixeira J; Donahoe PK
Development; 2006 Jun; 133(12):2359-69. PubMed ID: 16687449
[TBL] [Abstract][Full Text] [Related]
14. Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival.
Chauvin M; Garambois V; Choblet S; Colombo PE; Chentouf M; Gros L; De Brauwere DP; Duonor-Cerutti M; Dumas K; Robert B; Jarlier M; Martineau P; Navarro-Teulon I; Pépin D; Chardès T; Pèlegrin A
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34013359
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of steroidogenesis in Leydig cells by Müllerian-inhibiting substance.
Fynn-Thompson E; Cheng H; Teixeira J
Mol Cell Endocrinol; 2003 Dec; 211(1-2):99-104. PubMed ID: 14656482
[TBL] [Abstract][Full Text] [Related]
16. Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer.
Basal E; Ayeni T; Zhang Q; Langstraat C; Donahoe PK; Pepin D; Yin X; Leof E; Cliby W
Curr Mol Med; 2016; 16(3):222-31. PubMed ID: 26917267
[TBL] [Abstract][Full Text] [Related]
17. Müllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications.
Teixeira J; Maheswaran S; Donahoe PK
Endocr Rev; 2001 Oct; 22(5):657-74. PubMed ID: 11588147
[TBL] [Abstract][Full Text] [Related]
18. Müllerian inhibiting substance inhibits branching morphogenesis and induces apoptosis in fetal rat lung.
Catlin EA; Tonnu VC; Ebb RG; Pacheco BA; Manganaro TF; Ezzell RM; Donahoe PK; Teixeira J
Endocrinology; 1997 Feb; 138(2):790-6. PubMed ID: 9003016
[TBL] [Abstract][Full Text] [Related]
19. Müllerian-inhibiting substance type II receptor expression and function in purified rat Leydig cells.
Lee MM; Seah CC; Masiakos PT; Sottas CM; Preffer FI; Donahoe PK; Maclaughlin DT; Hardy MP
Endocrinology; 1999 Jun; 140(6):2819-27. PubMed ID: 10342873
[TBL] [Abstract][Full Text] [Related]
20. The in vivo roles of müllerian-inhibiting substance.
Behringer RR
Curr Top Dev Biol; 1994; 29():171-87. PubMed ID: 7828438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
